News stories about Cytokinetics (NASDAQ:CYTK) have been trending somewhat positive on Tuesday, according to Accern Sentiment. Accern identifies negative and positive news coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Cytokinetics earned a news impact score of 0.08 on Accern’s scale. Accern also gave media headlines about the biopharmaceutical company an impact score of 44.8907010061329 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

Shares of Cytokinetics (NASDAQ:CYTK) traded up $0.02 during trading hours on Tuesday, reaching $8.22. 166,292 shares of the company traded hands, compared to its average volume of 350,707. The company has a market cap of $441.85, a P/E ratio of -4.91 and a beta of 1.03. The company has a debt-to-equity ratio of 0.14, a quick ratio of 7.60 and a current ratio of 7.60. Cytokinetics has a fifty-two week low of $7.00 and a fifty-two week high of $17.20.

CYTK has been the subject of a number of recent research reports. TheStreet downgraded shares of Cytokinetics from a “c” rating to a “d” rating in a report on Friday, October 27th. JMP Securities reaffirmed an “outperform” rating and set a $13.00 price target (down previously from $17.00) on shares of Cytokinetics in a report on Tuesday, November 21st. They noted that the move was a valuation call. Cantor Fitzgerald downgraded shares of Cytokinetics from an “overweight” rating to a “neutral” rating and cut their price target for the stock from $21.00 to $10.00 in a report on Wednesday, November 22nd. Needham & Company LLC downgraded shares of Cytokinetics from a “strong-buy” rating to a “buy” rating and cut their price target for the stock from $22.00 to $12.00 in a report on Tuesday, November 21st. Finally, ValuEngine downgraded shares of Cytokinetics from a “hold” rating to a “sell” rating in a report on Tuesday, November 21st. One research analyst has rated the stock with a sell rating, two have issued a hold rating and ten have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $17.91.

COPYRIGHT VIOLATION WARNING: This article was first published by Watch List News and is owned by of Watch List News. If you are reading this article on another publication, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The legal version of this article can be viewed at https://www.watchlistnews.com/cytokinetics-cytk-receiving-somewhat-positive-news-coverage-study-finds/1848266.html.

Cytokinetics Company Profile

Cytokinetics, Incorporated is a late-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions.

Insider Buying and Selling by Quarter for Cytokinetics (NASDAQ:CYTK)

Receive News & Ratings for Cytokinetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytokinetics and related companies with MarketBeat.com's FREE daily email newsletter.